Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
Gold Price Climbs Above $4,130 as Middle East Tensions Boost Safe-Haven Demand 
Japan PM Sanae Takaichi Unveils Growth Plan as BOJ Independence Concerns Lift Bond Yields 
Asian Stocks Rally on AI Spending Optimism as Middle East Tensions Push Oil to Six-Week High 
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors 
Chalco Shares Jump as Chinalco Plans Up to $300 Million Stake Increase 
South Korea Q2 GDP Beats Forecasts as AI Chip Exports Drive Growth 
Gold Price Surges Above $4,100 as Middle East Tensions Boost Safe-Haven Demand 
US Dollar Pauses Rally as Middle East Tensions Support Safe-Haven Demand 
KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
US Stock Exchanges Face Earnings Test as Trading Boom Meets Crypto Competition 
US Dollar Climbs to Weekly High as Middle East Tensions Lift Treasury Yields and Safe-Haven Demand 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Asian Currencies Hold Steady as Middle East Tensions Boost US Dollar, Oil Concerns 
Scandinavian Tobacco Group Sells BREAK and Moro Brands to Japan Tobacco for €176 Million 
GE Vernova Q2 Revenue Tops Estimates as Earnings Miss, Shares Slide Despite Higher 2026 Outlook 
Lotte Corporation, a South Korean multinational company that is also the fifth-largest chaebol in the country, is buying a Bristol-Myers Squibb bio facility in Syracuse, New York. Based on the reports, the sale deal is worth $160 million.
Bristol Myers Squibb is an American multinational pharmaceutical company, and it will be unloading its manufacturing plant in Syracuse. Its sale to Lotte Corporation also includes all the equipment in the facility.
Moreover, all the workers in the plant will also be continued to be employed after the sale, and this is part of the deal. This means that they will all be transferred and will start working under the said Korean company. Lotte is looking to close the acquisition deal within this year.
According to Korea Joongang Daily, Lotte Group’s board of directors approved the purchase of Bristol-Myers Squibb just late last week. The acquisition is part of the company’s preparations for the establishment of its own biopharmaceutical subsidiary called the Lotte Biologics.
It was previously reported that Lotte had already filed to trademark the said name with the Korea Intellectual Property Rights Information Service in April. Lotte's second-growth team head, Lee Won Jik, said that since the Syracuse plant has been producing drugs for a long time now, it would be easy for them to operate it once they take over.
Lotte will be upgrading the plant and renovating it as specified in the contract development and manufacturing organization (CDMO) orders. Once the contract is sealed and Lotte Biologics starts operating, it will be manufacturing $220 million worth of bioproducts over three years for Bristol-Myers Squibb. Lotte is also planning to develop its own medicines in the future.
“The East Syracuse site has been an important part of our company’s history and our manufacturing network for many decades, and we are confident that LOTTE will fully leverage the facility, its capabilities and its experienced workforce as it continues to play a vital role for patients around the world,” Bristol Myers Squibb’s Global Product Development’s executive vice president, Karin Shanahan, said in a press release.
She added, “We have taken a thoughtful approach to this decision and are confident this will best support the continued evolution of our manufacturing network and our mission to deliver innovative medicines that help patients prevail over serious diseases.”
